Intended for healthcare professionals

Can we afford it?

Barry Monk
The cost of new drugs is a major issue in the NHS; some of the recently introduced therapeutic agents are eye-wateringly expensive, and this can create challenging situations for those who struggle to do their best for individual patients, while their managers try to keep some sort of overall budgetary control. Dermatology is not immune to this, with important but expensive new treatments for psoriasis, melanoma and basal cell carcinoma.
Dermatology in practice 2015; 21(3): 71–71
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)